Viatris (VTRS) Depreciation & Amortization (CF) (2020 - 2026)
Viatris (VTRS) recorded quarterly Depreciation & Amortization (CF) of $676.1 million in Q1 2026, down 11.83% quarter-over-quarter from $766.8 million in Q4 2025, and up 1.72% on a YoY basis from $664.7 million in Q1 2025.
Viatris (VTRS) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Viatris' Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $676.1 million for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) rose 1.72% year-over-year to $676.1 million; the TTM figure through Mar 2026 stood at $2.8 billion (down 2.0% YoY), while the FY2025 annual figure was $2.8 billion, down 3.28% from the prior year.
- Depreciation & Amortization (CF) was $676.1 million for Q1 2026 at Viatris, down from $766.8 million in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $869.8 million in Q4 2022 to a low of $644.4 million in Q4 2023.
- Historically, Depreciation & Amortization (CF) has averaged $713.9 million across 5 years, with a median of $691.0 million in 2024.
- Biggest YoY gain for Depreciation & Amortization (CF) was 16.0% in 2022; the steepest drop was 48.26% in 2022.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $869.8 million in 2022, then slipped by 25.91% to $644.4 million in 2023, then gained by 15.8% to $746.2 million in 2024, then gained by 2.76% to $766.8 million in 2025, then retreated by 11.83% to $676.1 million in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $676.1 million (Q1 2026), $766.8 million (Q4 2025), and $688.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 239.00 Mn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 119.00 Mn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 22.60 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 7.20 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 172.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 19.43 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 21.95 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 22.68 Mn |
| 10 | Viatris | - | - | 1.16 Bn | 676.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 676.10 Mn |
| Mar 31, 2026 | 676.10 Mn |
| Dec 31, 2025 | 766.80 Mn |
| Dec 31, 2025 | 766.80 Mn |
| Sep 30, 2025 | 688.50 Mn |
| Sep 30, 2025 | 688.50 Mn |
| Jun 30, 2025 | 678.30 Mn |
| Jun 30, 2025 | 678.30 Mn |
| Mar 31, 2025 | 664.70 Mn |
| Mar 31, 2025 | 664.70 Mn |
| Dec 31, 2024 | 746.20 Mn |
| Dec 31, 2024 | 746.20 Mn |
| Sep 30, 2024 | 669.70 Mn |
| Sep 30, 2024 | 669.70 Mn |
| Jun 30, 2024 | 786.30 Mn |
| Jun 30, 2024 | 786.30 Mn |
| Mar 31, 2024 | 691.00 Mn |
| Mar 31, 2024 | 691.00 Mn |
| Dec 31, 2023 | 644.40 Mn |
| Dec 31, 2023 | 644.40 Mn |